A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

(1) USZ Zürich,Zürich,Switzerland

(2) Hospital General de Tomelloso Dept. of Digestive Health,Tomelloso,Spain

(3) Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany

(4) Technische Universität München,München,Germany

(5) Hospital Universitario de La Princesa,Madrid,Spain

(6) Hospital 12 de Octubre Dept. de Gastroenterologia,Madrid,Spain

(7) Sana Klinikum Lichtenberg,Berlin,Germany

(8) CRH Clinic Siloah,Hannover,Germany

(9) Universitätsspital Basel,Basel,Switzerland

(10) St. George`s University Hospitals,London,United Kingdom

(11) Otto von Guericke University,Madgeburg,Germany

(12) Academisch Med. Centrum Amsterdam,Amsterdam,Netherlands

(13) Dr. Falk Pharma GmbH,Freiburg,Germany

(14) University Hospital (CHUV),Lausanne,Switzerland

(15) Durham University,Durham,United Kingdom

(16) Swiss EoE Research Network,Olten,Switzerland



This item was part of the What's hot in eosinophilic oesophagitis (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

You may be interested in:

Surgery for refractory reflux disease: Risks and outcomes
English, Presentation, Clinical aspects, Oesophagus, Reflux disease, Surgical management, Upper GI surgery, 2012
Functional oesophageal disorders: Pro & Con
English, Presentation, Neurogastroenterology & Motility, Primary Care, 2018

Categorisation:

  • Format
    • Abstract
  • Year
    • 2019